+ ESCOZUL is a product that is still
under clinical research. It has been released to the public because
the results obtained with cancer patients are really promising and
does not cause side effects.
+ Currently, the research is on phase
3 where ESCOZUL's effect on patients with a determined level of cancer
and who are not using conventional therapy is being studied.
+ LABIOFAM
group, integrated by qualified researchers and scientists is the
only laboratory authorized by the Cuban Government to carry out a
research on ESCOZUL.
+ There is no scientific journal that
addresses the ESCOZUL topic. LABIOFAM believes that no conclusive
result will be released until the peptides with anticarcinogenic properties
have been isolated, in order to start the venom's industrial production.
+ The Misael
Bordier group exposes its results on-line, but they lack scientific
validity and are not published in scientific journals either.
+ The antiproliferative effect of the
ESCOZUL has been clearly manifested in the experimental tumor cell
lines. This means that somehow the ESCOZUL stops the cellular growth
of the tumor. The experiments performed in vitro and in mice give
to similar results.
+ The antiproliferative cell effect of
ESCOZUL becomes clearly apparent in the lines of experimental tumors.
This means that ESCOZUL somehow stops the tumor cell growth. Experiments
done in vitro as well as in mice show similar results. LABIOFAM treats
more than 2000 patients with terminal cancer who have been taking
ESCOZUL for more than 4 years. Among them, there are 187 patients
who were given only one month to live but have now been living 8 years
with a good quality of life.
+ 90% of LABIOFAM's patients have shown
improvement in their quality of life after 2 to 3 months of starting
the treatment.
+ ESCOZUL's anticarcinogenic
action mechanism is still now fully known although LABIOFAM offers
insights to a number of theories. |
|
+
In December 2005 we had the opportunity to attend, as listeners, the
I International Symposium of Toxinology that took place in Guantanamo
(Cuba). Various research works on the blue scorpion venom were presented
at this event. Except for LABIOFAM, the rest of the participants did
not contribute with anything of scientific nature or research about
ESCOZUL. Next, we present some of the research results that have been
developed by the LABIOFAM group until now:
Evaluation of the antitumoral activity of ESCOZUOZUL in human
tumors in vivo. (Phase III, in progress).
At this moment, LABIOFAM is developing the clinical trials in cancer
patients; therefore, the effects of ESCOZUL in humans can not be scientifically
demonstrated yet. However, there is a registry of patients treated
for more than 8 years and the results are very good.
LABIOFAM keeps a registry of the treated cases. The majority of its
patients present breast (23.44%), prostate (17.86%), lung (8.87%),
colon (8.72%) and brain cancer (8.21%). There is a large registry
of the positive effects of ESCOZUL in cancer patients. More than 25.000
persons have reported an improvement after having been treated with
ESCOZUL, even people to whom conventional therapy had not offered
any improvement. From a clinical point of view, 90% of LABIOFAM's
patients have shown an improvement in their quality of life 2 or 3
months after starting the treatment.
+ The main effects reported are:
- Remission of the tumor after a certain time of treatment
- Prolonged life of the patient.
- Appetite and sleep gain.
- Considerable pain reduction.
+ LABIOFAM specialists reported
amazing numbers about the life expectancy extension of stage 4 patients
with terminal prognosis. Currently, LABIOFAM treats more than 2000
cancer patients with terminal prognosis who have been taking ESCOZUL
for more than 4 years. Among them there are 187 patients who were
only given 1 month to live but have now been living 8 years of a very
good quality of life.
+  So,
how does ESCOZUL work? No one has a clear idea of ESCOZUL's anticarcinogenic
mechanism. There are many theories about a possible action through:
an inmune-modulator effect, angiogenesis inhibitor or an apoptosis
potentiator. LABIOFAM researchers explain that ESCOZUL firstly surrounds
cancer with proteins that stop its progression. This first action
does not allow cancer to spread. Secondly, ESCOZUL inhibits the growth
of blood vessels around cancer. This last action as an inhibitor of
angiogenesis causes the death of tumor cells since they can not live
without the nutrients carried by the blood. Of course, if the cancer
is very spread it is more difficult to surround and kill the tumor
cells. It is for this reason that researchers say ESCOZUL works better
when it is used during the early stages of the disease, but as it
has been said before cancer patients with terminal prognosis have
survived for more than 4 years taking ESCOZUL!
Evaluation of the venom's toxic effects when given to mice orally.
ESCOZUL does not cause any toxic side effect when taken orally. Experiments
were made upon mice which were given different doses of ESCOZUL (0
mg/Kg, 5 mg/Kg, 50 mg/Kg y 300 mg/Kg) orally during 14 days. During
this time, the mice showed different clinical signs such as: motor
function, reflex, convulsions, salivation, sedation, somnolence, skin
condition, mucosa, eyes and other organs. It was found that there
was no mortality, weight loss or alteration of the internal organs.
On the other hand it was observed sedation, a light locomotion slow
down and a reflex reduction.
Evaluation of the analgesic activity of the blue scorpion venom
(pain killer).
 Yes,
the ESCOZUL is a pain killer. The graphic shows the results of an
experimental model of chemical analgesia. Six groups of laboratory
mice subjected to different concentrations of ESCOZUL were examined,
a control (+) group subjected to ASA and a control (-) group without
any analgesic. The mice were induced pain by injecting acetic acid
into them after which the specialists counted the number of contortions
the mice suffered in a period of 10 minutes. The number of contortions
is a pain indicator. The different letters inside the bars indicate
significant statistical differences in the number of contortions between
treatments. On the contrary, the treatments with equal letters indicate
there are no differences between them. Thus, it can be observed that
ESCOZUL has analgesic activity and that there are no differences between
the treatment effects with ASA, 5, 10, 15, 20 and 50 mg/Kg of ESCOZUL.
The graphic shows the inhibition percentage of the contortions for
each treatment. It can be seen in the graphic that the treatments
with high concentrations of ESCOZUL can inhibit up to 55% of pain.
This experiment with mice could explain why cancer patients who are
treated with ESCOZUL show a pain reduction.
Evaluation of the anti-inflammatory activity of the blue scorpion
venom in experimental models of acute inflammation.
 The
graphic shows the results of the acute anti-inflammatory experimental
model. Three groups of laboratory mice subjected orally to different
concentrations of ESCOZUL were examined, a group control (+) subjected
to dexamet and a group control (-) without any anti-inflammatory.
They were induced the inflammation by injecting croton oil into them
and the effects were evaluated taken into account the mice's weight.
The different letters inside the bars show significant statistical
differences in weight between treatments, on the contrary, the treatments
with equal letters show there are no differences between them. Thus,
it can be seen that ESCOZUL has anti-inflammatory activity and that
there are no differences between the effects of treatments with 5,
10 and 20 mg/Kg of ESCOZUL. The graphic shows the percentage of the
inflammation inhibition for each treatment. It can be seen that the
treatments with high concentrations of ESCOZUL can get to inhibit
up to 38% of the inflammation. This experiment with mice could explain
why cancer patients who are treated with ESCOZUL show a reduction
in the appearance of edemas and inflammations.
Evaluation of the antiproliferative activity of ESCOZUL in cultures
of tumor cell lines in vitro.
 The
graphic shows the percentage of cell growth of different cell cultures
when treated with dissimilate doses of ESCOZUL. It can be observed
that ESCOZUL has antiproliferative activity and the more concentrated
the dose, the lower the cell proliferation will be. The greater reduction
was obtained for the lung and larynx cell lines.
Evaluation of the antitumoral activity in murine tumors in
vivo.
 The
following graphic shows the behavior of the tumor growth in four experimental
groups subjected to different doses of ESCOZUL. It can be seen that
ESCOZUL has antitumoral activity and the more concentrated the dose,
the more slowly the tumor will grow.
Biochemical characterization of the venom of the blue scorpion
Rhopalurus junceus.
This research is still under way and the results are kept secret.
The objective of this research is to identify the active principle
of the blue scorpion venom in order to obtain its synthesis at a later
stage. As far as we know, the active principle is composed of peptides
instead of large proteins.
|
|
